Oculis Holding AG Warrants (OCSAW)

• Market cap: $444M
• 1 day: 0.00%
• 5 days: 0.00%
• 1 month: 0.00%
• 3 months: 0.00%
• 6 months: 0.00%
• Year to date: 0.00%
• 1 year: 0.00%
• 5 years: 0.00%
• 10 years: 0.00%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Employees: 49

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.42% less ownership

Funds ownership: 1.07% [Q4 2024] → 0.65% (-0.42%) [Q1 2025]

13% less capital invested

Capital invested by funds: $2.45M [Q4 2024] → $2.14M (-$310K) [Q1 2025]

20% less funds holding

Funds holding: 15 [Q4 2024] → 12 (-3) [Q1 2025]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3